Symbols / CRSP
CRSP Chart
About
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.45B |
| Enterprise Value | 3.68B | Income | -581.60M | Sales | 3.51M |
| Book/sh | 20.04 | Cash/sh | 20.59 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -13.65 | PEG | — |
| P/S | 1552.45 | P/B | 2.83 | P/C | — |
| EV/EBITDA | -6.71 | EV/Sales | 1048.43 | Quick Ratio | 13.25 |
| Current Ratio | 13.32 | Debt/Eq | 10.76 | LT Debt/Eq | — |
| EPS (ttm) | -6.47 | EPS next Y | -4.16 | EPS Growth | — |
| Revenue Growth | -97.60% | Earnings | 2026-05-11 | ROA | -15.76% |
| ROE | -30.18% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -179.12% | Profit Margin | 0.00% | Shs Outstand | 95.99M |
| Shs Float | 92.39M | Short Float | 25.78% | Short Ratio | 12.17 |
| Short Interest | — | 52W High | 78.48 | 52W Low | 30.04 |
| Beta | 1.75 | Avg Volume | 1.73M | Volume | 1.69M |
| Target Price | $84.78 | Recom | Buy | Prev Close | $53.98 |
| Price | $56.77 | Change | 5.17% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$84.78
Mean price target
2. Current target
$57.78
Latest analyst target
3. DCF / Fair value
$-38.56
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$57.78
Low
$33.00
High
$315.00
Mean
$84.78
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-17 | main | Chardan Capital | Buy → Buy | $76 |
| 2026-02-13 | main | TD Cowen | Hold → Hold | $45 |
| 2026-02-13 | main | Evercore ISI Group | Outperform → Outperform | $74 |
| 2026-02-13 | main | Needham | Buy → Buy | $82 |
| 2026-01-30 | main | Citizens | Market Outperform → Market Outperform | $80 |
| 2025-12-23 | reit | Needham | Buy → Buy | $80 |
| 2025-12-23 | reit | Citizens | Market Outperform → Market Outperform | $86 |
| 2025-11-26 | main | Chardan Capital | Buy → Buy | $74 |
| 2025-11-12 | main | Citigroup | Buy → Buy | $77 |
| 2025-11-11 | main | RBC Capital | Sector Perform → Sector Perform | $50 |
| 2025-11-11 | main | Baird | Neutral → Neutral | $44 |
| 2025-11-10 | main | Needham | Buy → Buy | $80 |
| 2025-10-17 | main | B of A Securities | Buy → Buy | $93 |
| 2025-10-10 | reit | Needham | Buy → Buy | $81 |
| 2025-09-23 | reit | HC Wainwright & Co. | Buy → Buy | $80 |
| 2025-09-18 | init | JP Morgan | — → Overweight | $70 |
| 2025-08-07 | main | HC Wainwright & Co. | Buy → Buy | $80 |
| 2025-08-06 | main | Barclays | Equal-Weight → Equal-Weight | $56 |
| 2025-08-05 | main | Chardan Capital | Buy → Buy | $82 |
| 2025-08-05 | main | RBC Capital | Sector Perform → Sector Perform | $42 |
- CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock? - Yahoo Finance ue, 03 Feb 2026 08
- CRISPR Therapeutics Stock Sees RS Rating Rise To 73 - Investor's Business Daily ue, 24 Feb 2026 18
- Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off? - The Motley Fool Fri, 20 Feb 2026 17
- CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows - MarketBeat hu, 19 Feb 2026 17
- How FDA RMAT Status For Zugo-cel Amid Wider Losses At CRISPR Therapeutics (CRSP) Has Changed Its Investment Story - simplywall.st Mon, 23 Feb 2026 00
- (CRSP) Movement as an Input in Quant Signal Sets - Stock Traders Daily ue, 24 Feb 2026 00
- First Week of October 16th Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq Fri, 20 Feb 2026 17
- CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock? - Zacks Investment Research ue, 03 Feb 2026 08
- Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward (NASDAQ:CRSP) - Seeking Alpha hu, 19 Feb 2026 04
- Is It Time To Reassess CRISPR Therapeutics (CRSP) After Recent Share Price Rebound? - Yahoo Finance hu, 19 Feb 2026 20
- CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells $111,048.96 in Stock - MarketBeat Sat, 21 Feb 2026 01
- 2 Biotech Stocks That Could Soar This Year - The Motley Fool Mon, 12 Jan 2026 08
- Assessing CRISPR Therapeutics (CRSP) Valuation As FDA Draft Guidance Speeds Rare Disease Genome Editing Approvals - simplywall.st ue, 24 Feb 2026 08
- CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells $366,324.86 in Stock - MarketBeat Sat, 21 Feb 2026 00
- The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices - The Motley Fool Fri, 20 Feb 2026 14
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 6967 | 366325.0 | — | Sale at price 52.58 per share. | KULKARNI SAMARTH | Chief Executive Officer | — | 2026-02-19 00:00:00 | D |
| 1 | 2112 | 111049.0 | — | Sale at price 52.58 per share. | KASINGER JAMES R. | General Counsel | — | 2026-02-19 00:00:00 | D |
| 2 | 13250 | nan | — | — | KULKARNI SAMARTH | Chief Executive Officer | — | 2026-02-18 00:00:00 | D |
| 3 | 3825 | nan | — | — | KASINGER JAMES R. | General Counsel | — | 2026-02-18 00:00:00 | D |
| 4 | 90000 | 5166298.0 | — | Sale at price 51.61 - 60.23 per share. | KULKARNI SAMARTH | Chief Executive Officer | — | 2026-01-22 00:00:00 | D |
| 5 | 34972 | 2104965.0 | — | Sale at price 60.19 per share. | PRASAD RAJU | Chief Financial Officer | — | 2026-01-22 00:00:00 | D |
| 6 | 34972 | 1578986.0 | — | Conversion of Exercise of derivative security at price 45.15 per share. | PRASAD RAJU | Chief Financial Officer | — | 2026-01-22 00:00:00 | D |
| 7 | 29700 | 1786636.0 | — | Sale at price 60.00 - 60.21 per share. | PRASAD RAJU | Chief Financial Officer | — | 2026-01-06 00:00:00 | D |
| 8 | 29700 | 1335630.0 | — | Conversion of Exercise of derivative security at price 44.31 - 45.15 per share. | PRASAD RAJU | Chief Financial Officer | — | 2026-01-06 00:00:00 | D |
| 9 | 10000 | 559549.0 | — | Sale at price 55.10 - 56.89 per share. | PRASAD RAJU | Chief Financial Officer | — | 2025-12-22 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.09 | 0.09 | 0.09 | 0.00 |
| NormalizedEBITDA | -645.09M | -447.31M | -202.70M | -648.99M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -581.60M | -366.25M | -153.61M | -650.17M |
| ReconciledDepreciation | 19.48M | 19.26M | 19.84M | 24.17M |
| ReconciledCostOfRevenue | 213.48M | 120.67M | 130.25M | 110.25M |
| EBITDA | -645.09M | -447.31M | -202.70M | -648.99M |
| EBIT | -664.57M | -466.57M | -222.54M | -673.16M |
| NormalizedIncome | -581.60M | -366.25M | -153.61M | -650.17M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -581.60M | -366.25M | -153.61M | -650.17M |
| TotalExpenses | 664.57M | 501.57M | 592.54M | 673.60M |
| TotalOperatingIncomeAsReported | -664.57M | -466.57M | -222.54M | -673.16M |
| DilutedAverageShares | 89.93M | 84.36M | 79.22M | 77.75M |
| BasicAverageShares | 89.93M | 84.36M | 79.22M | 77.75M |
| DilutedEPS | -6.47 | -4.34 | -1.94 | -8.36 |
| BasicEPS | -6.47 | -4.34 | -1.94 | -8.36 |
| DilutedNIAvailtoComStockholders | -581.60M | -366.25M | -153.61M | -650.17M |
| NetIncomeCommonStockholders | -581.60M | -366.25M | -153.61M | -650.17M |
| NetIncome | -581.60M | -366.25M | -153.61M | -650.17M |
| NetIncomeIncludingNoncontrollingInterests | -581.60M | -366.25M | -153.61M | -650.17M |
| NetIncomeContinuousOperations | -581.60M | -366.25M | -153.61M | -650.17M |
| TaxProvision | 3.63M | 3.59M | 2.89M | -325.00K |
| PretaxIncome | -577.97M | -362.67M | -150.72M | -650.50M |
| OtherIncomeExpense | 86.61M | 103.90M | 71.82M | 22.66M |
| OtherNonOperatingIncomeExpenses | 86.61M | 103.90M | 71.82M | 22.66M |
| OperatingIncome | -664.57M | -466.57M | -222.54M | -673.16M |
| OperatingExpense | 451.09M | 380.90M | 462.29M | 563.35M |
| OtherOperatingExpenses | -3.51M | -2.31M | -1.21M | -762.00K |
| ResearchAndDevelopment | 381.06M | 310.24M | 387.33M | 461.64M |
| SellingGeneralAndAdministration | 73.54M | 72.98M | 76.16M | 102.46M |
| GeneralAndAdministrativeExpense | 73.54M | 72.98M | 76.16M | 102.46M |
| OtherGandA | 73.54M | 72.98M | 76.16M | 102.46M |
| GrossProfit | -213.48M | -85.67M | 239.75M | -109.81M |
| CostOfRevenue | 213.48M | 120.67M | 130.25M | 110.25M |
| TotalRevenue | 0.00 | 35.00M | 370.00M | 436.00K |
| OperatingRevenue | 0.00 | 35.00M | 370.00M | 436.00K |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 115.32K | 170.32K | 170.32K | 180.32K |
| OrdinarySharesNumber | 95.89M | 85.74M | 80.04M | 78.51M |
| ShareIssued | 96.01M | 85.91M | 80.21M | 78.69M |
| TotalDebt | 206.75M | 223.69M | 238.63M | 244.02M |
| TangibleBookValue | 1.92B | 1.93B | 1.88B | 1.88B |
| InvestedCapital | 1.92B | 1.93B | 1.88B | 1.88B |
| WorkingCapital | 1.84B | 1.85B | 1.80B | 1.73B |
| NetTangibleAssets | 1.92B | 1.93B | 1.88B | 1.88B |
| CapitalLeaseObligations | 206.75M | 223.69M | 238.63M | 244.02M |
| CommonStockEquity | 1.92B | 1.93B | 1.88B | 1.88B |
| TotalCapitalization | 1.92B | 1.93B | 1.88B | 1.88B |
| TotalEquityGrossMinorityInterest | 1.92B | 1.93B | 1.88B | 1.88B |
| StockholdersEquity | 1.92B | 1.93B | 1.88B | 1.88B |
| GainsLossesNotAffectingRetainedEarnings | 4.82M | 1.84M | 1.91M | -15.65M |
| OtherEquityAdjustments | 4.82M | 1.84M | 1.91M | -15.65M |
| TreasuryStock | 60.00K | 62.00K | 62.00K | 63.00K |
| RetainedEarnings | -1.95B | -1.37B | -999.70M | -846.09M |
| AdditionalPaidInCapital | 3.86B | 3.29B | 2.88B | 2.73B |
| CapitalStock | 3.09M | 2.70M | 2.50M | 2.44M |
| CommonStock | 3.09M | 2.70M | 2.50M | 2.44M |
| TotalLiabilitiesNetMinorityInterest | 343.43M | 309.95M | 346.77M | 367.58M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 194.31M | 222.17M | 237.98M | 246.47M |
| OtherNonCurrentLiabilities | 6.14M | 3.44M | 958.00K | 5.97M |
| NonCurrentDeferredLiabilities | 0.00 | 12.32M | 14.01M | 12.32M |
| NonCurrentDeferredRevenue | 0.00 | 12.32M | 14.01M | 12.32M |
| LongTermDebtAndCapitalLeaseObligation | 188.17M | 206.41M | 223.01M | 228.18M |
| LongTermCapitalLeaseObligation | 188.17M | 206.41M | 223.01M | 228.18M |
| CurrentLiabilities | 149.12M | 87.78M | 108.79M | 121.11M |
| OtherCurrentLiabilities | 13.11M | 10.42M | 5.14M | 20.00K |
| CurrentDeferredLiabilities | 15.77M | 3.85M | 4.11M | 0.00 |
| CurrentDeferredRevenue | 15.77M | 3.85M | 4.11M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 18.58M | 17.29M | 15.62M | 15.84M |
| CurrentCapitalLeaseObligation | 18.58M | 17.29M | 15.62M | 15.84M |
| PayablesAndAccruedExpenses | 101.66M | 56.23M | 83.92M | 105.25M |
| CurrentAccruedExpenses | 89.41M | 41.07M | 45.34M | 77.68M |
| Payables | 12.25M | 15.16M | 38.59M | 27.56M |
| TotalTaxPayable | 1.11M | 451.00K | 438.00K | 135.00K |
| AccountsPayable | 11.14M | 14.71M | 38.15M | 27.43M |
| TotalAssets | 2.27B | 2.24B | 2.23B | 2.24B |
| TotalNonCurrentAssets | 279.57M | 304.90M | 321.49M | 390.03M |
| OtherNonCurrentAssets | 32.00M | 27.35M | 13.57M | 16.27M |
| InvestmentsAndAdvances | 0.00 | 1.97M | 53.13M | 0.00 |
| InvestmentinFinancialAssets | 0.00 | 1.97M | 53.13M | 0.00 |
| AvailableForSaleSecurities | 1.97M | 53.13M | ||
| GoodwillAndOtherIntangibleAssets | 0.00 | 16.00K | 71.00K | 125.00K |
| NetPPE | 247.57M | 277.55M | 305.94M | 320.56M |
| AccumulatedDepreciation | -91.05M | -72.27M | -53.43M | -33.83M |
| GrossPPE | 338.63M | 349.83M | 359.37M | 354.39M |
| Leases | 146.67M | 145.85M | 143.26M | 141.68M |
| ConstructionInProgress | 3.96M | 6.12M | 8.86M | 6.16M |
| OtherProperties | 175.30M | 185.47M | 195.40M | 194.82M |
| MachineryFurnitureEquipment | 12.71M | 12.39M | 11.85M | 11.73M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.99B | 1.94B | 1.91B | 1.85B |
| OtherCurrentAssets | 9.84M | 8.31M | 14.39M | 37.71M |
| PrepaidAssets | 38.08M | |||
| Receivables | 0.00 | 25.00M | 200.00M | 0.00 |
| AccountsReceivable | 0.00 | 25.00M | 200.00M | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 1.98B | 1.90B | 1.69B | 1.82B |
| OtherShortTermInvestments | 1.63B | 1.61B | 1.30B | 1.60B |
| CashAndCashEquivalents | 347.56M | 298.26M | 389.48M | 211.88M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -370.93M | -144.68M | -272.35M | -532.93M |
| IssuanceOfCapitalStock | 398.09M | 300.69M | 32.72M | 970.00K |
| CapitalExpenditure | -25.91M | -1.90M | -11.97M | -37.19M |
| EndCashPosition | 359.08M | 309.78M | 401.07M | 224.06M |
| BeginningCashPosition | 309.78M | 401.07M | 224.06M | 939.94M |
| EffectOfExchangeRateChanges | 95.00K | -21.00K | 73.00K | -80.00K |
| ChangesInCash | 49.21M | -91.27M | 176.94M | -715.80M |
| FinancingCashFlow | 426.03M | 331.98M | 62.66M | 38.59M |
| CashFlowFromContinuingFinancingActivities | 426.03M | 331.98M | 62.66M | 38.59M |
| ProceedsFromStockOptionExercised | 27.94M | 31.29M | 29.94M | 37.62M |
| NetCommonStockIssuance | 398.09M | 300.69M | 32.72M | 970.00K |
| CommonStockIssuance | 398.09M | 300.69M | 32.72M | 970.00K |
| InvestingCashFlow | -31.80M | -280.48M | 374.65M | -258.65M |
| CashFlowFromContinuingInvestingActivities | -31.80M | -280.48M | 374.65M | -258.65M |
| NetInvestmentPurchaseAndSale | -5.89M | -278.58M | 386.62M | -221.47M |
| SaleOfInvestment | 1.01B | 1.21B | 1.45B | 1.20B |
| PurchaseOfInvestment | -1.02B | -1.49B | -1.07B | -1.42B |
| NetIntangiblesPurchaseAndSale | -25.00M | 0.00 | -2.50M | 0.00 |
| PurchaseOfIntangibles | -25.00M | 0.00 | -2.50M | 0.00 |
| NetPPEPurchaseAndSale | -914.00K | -1.90M | -9.47M | -37.19M |
| PurchaseOfPPE | -914.00K | -1.90M | -9.47M | -37.19M |
| OperatingCashFlow | -345.01M | -142.77M | -260.38M | -495.74M |
| CashFlowFromContinuingOperatingActivities | -345.01M | -142.77M | -260.38M | -495.74M |
| ChangeInWorkingCapital | 71.88M | 156.27M | -193.59M | 19.84M |
| ChangeInOtherWorkingCapital | -5.61M | -6.36M | 3.33M | 14.30M |
| ChangeInOtherCurrentLiabilities | 4.26M | 9.62M | 110.00K | -1.52M |
| ChangeInPayablesAndAccruedExpense | 44.89M | -27.28M | -20.25M | 5.16M |
| ChangeInPrepaidAssets | 3.34M | 5.29M | 23.22M | 1.60M |
| ChangeInReceivables | 25.00M | 175.00M | -200.00M | 305.00K |
| ChangesInAccountReceivables | 25.00M | 175.00M | -200.00M | 305.00K |
| OtherNonCashItems | 72.72M | -38.62M | -14.04M | 12.47M |
| StockBasedCompensation | 72.50M | 86.57M | 81.03M | 97.95M |
| AmortizationOfSecurities | 14.11M | |||
| DepreciationAmortizationDepletion | 19.48M | 19.26M | 19.84M | 24.17M |
| DepreciationAndAmortization | 19.48M | 19.26M | 19.84M | 24.17M |
| Depreciation | 19.40M | 19.20M | ||
| EarningsLossesFromEquityInvestments | 0.00 | |||
| GainLossOnSaleOfBusiness | 0.00 | |||
| NetIncomeFromContinuingOperations | -581.60M | -366.25M | -153.61M | -650.17M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CRSP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|